Related Experiment Video
Updated: Aug 27, 2025
08:53
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
501
Biomaterials-Enabled Antithrombotics: Recent Advances and Emerging Strategies
Macy M Hale1, Scott H Medina1,2
1Department of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania 16802-4400, United States.
Molecular Pharmaceutics
|September 23, 2022
Summary
Biomaterials offer advanced solutions for antithrombotic and thrombolytic therapies, overcoming limitations of traditional drugs. These innovative materials promise more precise, durable, and safer clot prevention and removal.
Area of Science:
- Biomaterials Science
- Cardiovascular Medicine
- Pharmacology
Background:
- Antithrombotic and thrombolytic therapies are crucial for managing blood clots but face challenges like short half-lives and off-target effects.
- Current treatments have limitations including potential for overdosing and poor patient compliance.
Purpose of the Study:
- To review the current state of anticoagulant and thrombolytic biomaterials.
- To explore how biomaterials can overcome limitations of conventional antithrombotic agents.
- To highlight advancements in precision medicine for cardiovascular applications.
Main Methods:
- Discussion of biomaterial formulation strategies across nano to macro scales.
- Analysis of material properties influencing controlled drug release kinetics.
- Summary of clot-specific drug targeting mechanisms.
Main Results:
- Preclinical efficacy of biomaterial-based therapies in cardiovascular conditions like stroke and myocardial infarction.
- Contrasting the performance of various biomaterial approaches.
- Identification of key material properties for enhanced antithrombotic action.
Conclusions:
- Biomaterials offer significant potential to improve antithrombotic and thrombolytic therapies.
- Ongoing research focuses on bioresponsive 'smart' biomaterials for precision cardiology.
- These advancements pave the way for safer and more effective clot management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
615
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
615
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
857
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
857
01:26Atherosclerosis III: Management
24
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
24
01:27Peripheral Artery Disease III: Interprofessional Care
23
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
23